Waystar Holding (WAY) is back in focus after a recent Overweight rating from KeyBanc Capital Markets highlighted its role in healthcare payments, strong client adoption of its AI powered platform, and solid customer satisfaction metrics.

The recent 9.5% single day share price gain and 17.9% 7 day share price return suggest short term momentum is building for Waystar Holding, even though the year to date share price return is down 25.2% and the 1 year total shareholder return is down 40.4%.

If you are tracking how AI is reshaping healthcare payments, it can be useful to widen the lens and review 40 healthcare AI stocks

Waystar Holding now trades at a discount to both analyst targets and some intrinsic value estimates, even after its recent bounce. This raises a key question for investors: Is this genuine mispricing, or is the market already factoring in expectations about future growth?

Most Popular Narrative: 30.6% Undervalued

With Waystar Holding last closing at $23.46 against a narrative fair value estimate of $33.83, the gap between price and modeled value is hard to ignore.

The acquisition of Iodine Software, a leading provider of AI-powered clinical intelligence, will expand Waystar's total addressable market by over 15%, accelerate its product roadmap, and immediately boost gross margins and adjusted EBITDA margins, setting up compounding, long-term revenue and earnings growth.

Want to see what kind of revenue pace, margin profile, and future earnings multiple it takes to back that $33.83 figure? The most followed narrative lays out an aggressive earnings ramp, richer profitability, and a premium valuation that assumes Waystar Holding earns its place alongside higher growth healthcare software peers.

Result: Fair Value of $33.83 (UNDERVALUED)

However, investors in Waystar Holding also need to factor in that higher leverage from the US$1.25b Iodine deal and potential pricing pressure from larger healthcare clients could challenge this upbeat narrative.

Another View: What Multiples Say About Waystar Holding

The narrative fair value suggests Waystar Holding is undervalued, but the current P/E of 35.7x tells a more cautious story. It sits above the global Healthcare Services average of 27.1x and above a fair ratio of 30x, even though it is below peers at 46.5x. Is the discount to peers a genuine opportunity, or is the premium to the fair ratio pointing to valuation risk if expectations cool?

For a closer look at how this pricing gap could close over time, including where the fair ratio might matter most, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and caution around Waystar Holding feels familiar, it is a good moment to move fast, test the numbers yourself, then weigh the 4 key rewards.

Looking for more investment ideas beyond Waystar Holding?

If the Waystar Holding story has you thinking more broadly about your portfolio, this is a good moment to scan other opportunities before the next move.

• Target potential mispricing by reviewing companies on the 44 high quality undervalued stocks that combine attractive valuations with solid underlying metrics.
• Prioritize resilience by checking the 74 resilient stocks with low risk scores for stocks that pair steadier risk profiles with more robust business fundamentals.
• Spot under-the-radar opportunities by using the screener containing 18 high quality undiscovered gems that highlight quality businesses still off many investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.